[go: up one dir, main page]

EA200801909A1 - Соединения пиридина для лечения заболеваний, опосредованных действием простагландина - Google Patents

Соединения пиридина для лечения заболеваний, опосредованных действием простагландина

Info

Publication number
EA200801909A1
EA200801909A1 EA200801909A EA200801909A EA200801909A1 EA 200801909 A1 EA200801909 A1 EA 200801909A1 EA 200801909 A EA200801909 A EA 200801909A EA 200801909 A EA200801909 A EA 200801909A EA 200801909 A1 EA200801909 A1 EA 200801909A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prostaglandine
treatment
diseases mediated
pyridine compounds
compounds
Prior art date
Application number
EA200801909A
Other languages
English (en)
Inventor
Джерард Мартин Пол Гиблин
Адриан Холл
Дэвид Нейджел Херст
Дерек Энтони Ролингз
Тициана Скоччитти
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35735391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0428263A external-priority patent/GB0428263D0/en
Priority claimed from GB0508458A external-priority patent/GB0508458D0/en
Priority claimed from GB0524675A external-priority patent/GB0524675D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200801909A1 publication Critical patent/EA200801909A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Соединения формулы (I) или их фармацевтически приемлемые производные, в которых X, Y, Z, R, R, R, R, R, Rи Rтакие, как определены в описании, способ получения таких соединений, фармацевтические композиции, содержащие такие соединения, и применением таких соединений в медицине (антагонисты рецептора ЕР).
EA200801909A 2004-12-23 2005-12-21 Соединения пиридина для лечения заболеваний, опосредованных действием простагландина EA200801909A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds
GB0508458A GB0508458D0 (en) 2005-04-26 2005-04-26 Compounds
GB0524675A GB0524675D0 (en) 2005-12-02 2005-12-02 Compounds

Publications (1)

Publication Number Publication Date
EA200801909A1 true EA200801909A1 (ru) 2009-06-30

Family

ID=35735391

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200801909A EA200801909A1 (ru) 2004-12-23 2005-12-21 Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
EA200701324A EA200701324A1 (ru) 2004-12-23 2005-12-21 Соединения пиридина для лечения заболеваний, опосредованных действием простагландина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200701324A EA200701324A1 (ru) 2004-12-23 2005-12-21 Соединения пиридина для лечения заболеваний, опосредованных действием простагландина

Country Status (20)

Country Link
US (2) US20100137378A1 (ru)
EP (2) EP2053042A1 (ru)
JP (1) JP2008525363A (ru)
KR (1) KR20070091301A (ru)
AR (1) AR052429A1 (ru)
AT (1) ATE424386T1 (ru)
AU (1) AU2005318372A1 (ru)
BR (1) BRPI0519398A2 (ru)
CA (1) CA2592442A1 (ru)
DE (1) DE602005013116D1 (ru)
EA (2) EA200801909A1 (ru)
ES (1) ES2321535T3 (ru)
IL (1) IL183781A0 (ru)
MA (1) MA29082B1 (ru)
MX (1) MX2007007830A (ru)
NO (1) NO20073332L (ru)
PE (2) PE20060838A1 (ru)
TW (1) TW200640865A (ru)
UY (1) UY29298A1 (ru)
WO (1) WO2006066968A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608825D0 (en) * 2006-05-04 2006-06-14 Glaxo Group Ltd Compounds
CA2687764A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
AR076373A1 (es) 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
SG178109A1 (en) 2009-07-31 2012-03-29 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2570125A1 (en) * 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
SG11201609974PA (en) 2014-06-03 2016-12-29 Actelion Pharmaceuticals Ltd Pyrazole compounds and their use as t-type calcium channel blockers
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
UA124708C2 (uk) 2016-09-30 2021-11-03 Вертекс Фармасьютікалз Інкорпорейтед Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2017378092B2 (en) 2016-12-16 2023-11-23 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
WO2018141961A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
KR102606188B1 (ko) 2017-08-02 2023-11-23 버텍스 파마슈티칼스 인코포레이티드 피롤리딘 화합물을 제조하기 위한 공정
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471276A (en) 1975-01-22 1977-04-21 Nippon Shinyaku Co Ltd 5-benzylpicolinic acid deri vatives
EP0388682A1 (de) 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1995017888A1 (en) 1993-12-30 1995-07-06 Smithkline Beecham Corporation Phenylmethyl hexanamides, and the use thereof
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ES2183935T3 (es) 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
UA57002C2 (ru) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Производное (метилсульфонил)фенил-2-(5н)-фуранона, фармацевтическая композиция и способ лечения
DK0892791T3 (da) 1996-04-12 2003-06-23 Searle & Co N-[[4-(5-methyl-3-phenylisoxazol-4-yl]-phenyl]-sulfonylpropylamid og dets natriumsalt som prodrugs for COX-2-inhibitorer
CN1152863C (zh) 1996-07-18 2004-06-09 麦克弗罗斯特(加拿大)公司 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE69816651T2 (de) 1997-09-05 2004-04-01 Glaxo Group Ltd., Greenford 2,3-diaryl-pyrazolo[1,5-b]pyridazin derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
DE69919887T2 (de) 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
ES2213601T3 (es) 1999-09-14 2004-09-01 MERCK FROSST CANADA & CO. Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimiento de tratamiento.
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US7232821B2 (en) 2002-04-08 2007-06-19 Glaxo Group Limited (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
DE60334015D1 (de) 2002-10-30 2010-10-14 Merck Frosst Canada Ltd Pyridopyrrolizin- und pyridoindolizinderivate
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
GB0306329D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0323585D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323584D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
EP1675832B1 (en) 2003-10-24 2008-02-20 Glaxo Group Limited Heterocyclyl compounds
GB0328024D0 (en) 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
GB0410121D0 (en) 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
JP2008525363A (ja) 2008-07-17
IL183781A0 (en) 2007-09-20
TW200640865A (en) 2006-12-01
ES2321535T3 (es) 2009-06-08
UY29298A1 (es) 2006-05-31
CA2592442A1 (en) 2006-06-29
EP2053042A1 (en) 2009-04-29
US7759369B2 (en) 2010-07-20
US20080249138A1 (en) 2008-10-09
KR20070091301A (ko) 2007-09-10
NO20073332L (no) 2007-09-17
US20100137378A1 (en) 2010-06-03
MA29082B1 (fr) 2007-12-03
EA200701324A1 (ru) 2007-10-26
EP1833795B1 (en) 2009-03-04
MX2007007830A (es) 2007-07-25
BRPI0519398A2 (pt) 2009-01-20
AU2005318372A1 (en) 2006-06-29
EP1833795A1 (en) 2007-09-19
AR052429A1 (es) 2007-03-21
PE20081440A1 (es) 2008-12-31
PE20060838A1 (es) 2006-10-12
WO2006066968A1 (en) 2006-06-29
ATE424386T1 (de) 2009-03-15
DE602005013116D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
SE0402735D0 (sv) Novel compounds
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
NO20070137L (no) Heterocykliske antivirale forbindelser
TW200613243A (en) Novel compounds
NO20083585L (no) Hetero-bisykliske antivirale forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
CY1107856T1 (el) Παραγωγα ιμιδαζολιου ως ανταγωνιστες υποδοχεα γλουταμινικου
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ATE386725T1 (de) Heterocyclylverbindungen
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
NO20083583L (no) Heterosykliske antivirale forbindelser
DE60208178D1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
TW200639156A (en) New compounds
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
SE0401655D0 (sv) New compounds